Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
ELCC 2017
The 7th European Lung Cancer Conference
Access to all presentations that took place at ELCC 2017 in Geneva, Switzerland
Presentation Date(s):- May 5 – 8, 2017
- Total Presentations: 359
-
+
The role of antiangiogenic agents in NSCLC: Are we making progress?
- Type: Young Oncologist session
- Presentations: 3
- Moderators:M. Reck
- Coordinates: 5/07/2017, 08:00 - 08:50, Room X
-
+
State of the art in first and subsequent lines of the NSCLC treatment
08:00 - 08:20 | Author(s): B. Besse
- Abstract
No abstract available for this presentation
-
+
Biomarker approaches for optimisation of antiangiogenic therapy
08:20 - 08:40 | Author(s): M. Reck
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Discussion
08:40 - 08:50
- Abstract
No abstract available for this presentation
-
+
Management of NSCLC with resistance to first line targeted therapy
- Type: Educational session
- Presentations: 5
- Moderators:L. Horn
- Coordinates: 5/07/2017, 09:00 - 10:30, Room B
-
+
Management of T790M positive disease after EGFR TKI failure
09:00 - 09:20 | Author(s): L. Horn
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Management of T790M negative disease after EGFR TKI failure
09:20 - 09:40 | Author(s): M. Krebs
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Management of drug resistance in ALK positive NSCLC
09:40 - 10:00 | Author(s): D.S. Tan
- Abstract
No abstract available for this presentation
-
+
Management of resistance in other targets beyond ALK and EGFR
10:00 - 10:20 | Author(s): L. Friboulet
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Questions and Answers
10:20 - 10:30
- Abstract
No abstract available for this presentation
-
+
SCLC and early stage NSCLC
- Type: Proffered Paper session
- Presentations: 7
- Moderators:S. Popat
- Coordinates: 5/07/2017, 09:00 - 10:30, Room C
-
+
44O - Validation of the prognostic value of 8th edition revisions of the AJCC staging system for non-small cell lung cancer: A SEER database analysis
09:00 - 09:12 | Author(s): O. Abdel-Rahman
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
59O - The impact of EGFR mutations on the prognosis of resected non-small cell lung cancer: A meta-analysis of literatures
09:12 - 09:24 | Author(s): W. Liang
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
60O - The benchmark of examined lymph node count in node positive NSCLC patients: A populational validation with SEER database
09:24 - 09:36 | Author(s): W. Liang
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Invited Discussant 44O, 59O and 60O
09:36 - 09:51 | Author(s): W.E.E. Eberhardt
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
51O - Early limited-stage small cell lung cancer: Sub-group analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial
09:51 - 10:03 | Author(s): A. Salem
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
LBA2_PR - Use of G-CSF and prophylactic antibiotics with concurrent chemo-radiotherapy in limited-stage small cell lung cancer: Results from the Phase III CONVERT trial
10:03 - 10:15 | Author(s): F. Gomes
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Invited Discussant 51O and LBA2_PR
10:15 - 10:30 | Author(s): S. Popat
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Is there a role for second-line immunotherapy in patients with PD-L1 negative NSCLC?
- Type: Controversy session
- Presentations: 4
- Moderators:M. Reck
- Coordinates: 5/07/2017, 09:15 - 10:15, Room A
-
+
Introduction and first vote
09:15 - 09:25 | Author(s): M. Reck
- Abstract
No abstract available for this presentation
-
+
Yes
09:25 - 09:45 | Author(s): R. Herbst
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
No
09:45 - 10:05 | Author(s): B. Besse
- Abstract
No abstract available for this presentation
-
+
Second vote and conclusions
10:05 - 10:15 | Author(s): L. Paz-Ares
- Abstract
No abstract available for this presentation
-
+
Molecular understanding of lung cancer: The role of the host and environment
- Type: Educational session
- Presentations: 5
- Moderators:D.P. Carbone
- Coordinates: 5/07/2017, 11:00 - 12:30, Room B
-
+
Role of the microbiome in lung cancer
11:00 - 11:20 | Author(s): W.O. Cookson
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Tumour clonal symbiosis
11:20 - 11:40 | Author(s): M. Janiszewska
- Abstract
No abstract available for this presentation
-
+
Homotypic and heterotypic interactions in lung carcinogenesis
11:40 - 12:00 | Author(s): L. Montuenga
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Tumour mutations that alter antigen presentation/signalling
12:00 - 12:20 | Author(s): M. Meyerson
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Questions and Answers
12:20 - 12:30
- Abstract
No abstract available for this presentation
-
+
SCLC: New insights
- Type: Educational session
- Presentations: 5
- Moderators:N. Reguart
- Coordinates: 5/07/2017, 11:00 - 12:30, Room C
-
+
What is the optimal thoracic radiotherapy in limited stage SCLC?
11:00 - 11:20 | Author(s): C. Faivre-Finn
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Can brain control be improved beyond PCI?
11:20 - 11:40 | Author(s): E. Gkika
- Abstract
No abstract available for this presentation
-
+
New therapies, new era?
11:40 - 12:00 | Author(s): N. Reguart
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
What can CDX models teach us?
12:00 - 12:20 | Author(s): C. Dive
- Abstract
No abstract available for this presentation
-
+
Questions and Answers
12:20 - 12:30
- Abstract
No abstract available for this presentation
-
+
What should non-surgeons expect from surgeons?
- Type: Educational session
- Presentations: 5
- Moderators:R..A. Stahel
- Coordinates: 5/07/2017, 11:00 - 12:30, Room A
-
+
Minimal requirements for surgical participation in CT screening programmes
11:00 - 11:20 | Author(s): G. Veronesi
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Surgeon-led randomised trials: The case of mesothelioma
11:20 - 11:40 | Author(s): J. Edwards
- Abstract
No abstract available for this presentation
-
+
The approach of surgeons towards N2 NSCLC
11:40 - 12:00 | Author(s): G. Massard
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
The impact of international surgical registries on multidisciplinary decisions: The case of thymic tumours and NET
12:00 - 12:20 | Author(s): P.L. Filosso
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Questions and Answers
12:20 - 12:30
- Abstract
No abstract available for this presentation
-
+
Poster Display Session
- Type: Poster Display Session
- Presentations: 142
- Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1
-
+
Tumour biology and pathology
12:30 - 12:30
- Abstract
No abstract available for this presentation
-
+
4P - PD-L1 in NSCLC cytology
12:30 - 12:30 | Author(s): M. Kovacevic
- Abstract
Loading... -
+
5P - Repeated biopsy for mutational analysis on EGFR-mutated non-small cell lung cancer (EGFR-NSCLC): Feasibility and safety
12:30 - 12:30 | Author(s): G. Anguera
- Abstract
Loading... -
+
6P - Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib
12:30 - 12:30 | Author(s): X. Wang
- Abstract
Loading... -
+
7P - Population-level effect of targeted therapy in patients with advanced pulmonary adenocarcinoma: A Swiss prospective cohort study
12:30 - 12:30 | Author(s): C. Schwegler
- Abstract
Loading... -
+
8P - Expression of genes associated with anti-viral response in EGFR mutant non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Author(s): N. Karachaliou
- Abstract
Loading... -
+
9P - Knockdown of MFN2 gene expression inhibits lung adenocarcinoma cell proliferation
12:30 - 12:30 | Author(s): Y. Lou
- Abstract
Loading... -
+
10P - In vivo evaluation of combertestatin A-4 phosphate for lung cancer by bioluminescence imaging and multispectral optoacoustic tomography
12:30 - 12:30 | Author(s): L. Liu
- Abstract
Loading... -
+
11P - Prognostic significance of different immunohistochemical markers in small cell lung cancer
12:30 - 12:30 | Author(s): E. Gkika
- Abstract
Loading... -
+
12P - Thyroid transcription factor-1 as a prognosticator in patients with metastatic lung adenocarcinoma without EGFR sensitizing mutations
12:30 - 12:30 | Author(s): J.Y. Park
- Abstract
Loading... -
+
13P - Characterizing the DNA damage response in putative stem cells of resected normal lung and matched NSCLC patient samples
12:30 - 12:30 | Author(s): T.M. Marti
- Abstract
Loading... -
+
14P - Histone H2AX phosphorylation increases apoptosis of lung cancer cells by miR-3196/PUMA pathway
12:30 - 12:30 | Author(s): C. Lu
- Abstract
Loading... -
+
15P - PLGF regulates crosstalk between non-small cell lung cancer cells and tumor-associated macrophages in cancer vascularization and growth
12:30 - 12:30 | Author(s): W. Zhang
- Abstract
Loading... -
+
16P - Carvacrol induces growth inhibition and circumvents chemoresistance via inhibition of STAT3/Skp2/p27 pathway in non-small lung cancer cells
12:30 - 12:30 | Author(s): K. Kim
- Abstract
Loading... -
+
Prevention, Early detection, Epidemiology, Tobacco control
12:30 - 12:30
- Abstract
No abstract available for this presentation
-
+
19P - Domestic cooking fuel as a risk factor for lung cancer in women: A case control study
12:30 - 12:30 | Author(s): S.S. Katpattil
- Abstract
Loading... -
+
21P - The efficacy of combination therapy with varenicline and bupropion for smoking cessation
12:30 - 12:30 | Author(s): D.A. Johns
- Abstract
Loading... -
+
23P - Pictorial warning on cigarette packets and its role in tobacco cessation: Questionnaire survey among cigarette smokers in Chennai
12:30 - 12:30 | Author(s): C.J.K. Francis
- Abstract
Loading... -
+
25P - Tobacco consumption pattern among auto rickshaw drivers in Chennai city, Tamil Nadu, India
12:30 - 12:30 | Author(s): D.L. Francis
- Abstract
Loading... -
+
26P - Smoking habits and awareness about anti-smoking acts among general public in Gurgaon, Haryana, India
12:30 - 12:30 | Author(s): C.J.K. Francis
- Abstract
Loading... -
+
27P - Factors causing treatment delays and its impact on treatment outcome in patients of lung cancer: An analysis
12:30 - 12:30 | Author(s): D. Kumar
- Abstract
Loading... -
+
28P - Impact of a pharmaceutical consultation: Review of a pilot study
12:30 - 12:30 | Author(s): E. Clou
- Abstract
Loading... -
+
29P - Baseline characteristics of participants in pl-208: A multi-center trial of the prolung test™ (Transthoracic Bioconductance Measurement) as an adjunct to CT chest scans for the risk stratification of patients with pulmonary lesions suspicious for lung cancer
12:30 - 12:30 | Author(s): R.C. Yung
- Abstract
Loading... -
+
Translational research
12:30 - 12:30
- Abstract
No abstract available for this presentation
-
+
31P - Targeted therapy for patients with ALK positive NSCLC: Results from the transalpine cohort
12:30 - 12:30 | Author(s): C. Britschgi
- Abstract
Loading... -
+
32P - Effects of BTK inhibitor on gefitinib-resistance non-small cell lung cancer
12:30 - 12:30 | Author(s): T. Hong
- Abstract
Loading... -
+
33P - The screening and characterization of aptamer against gefitinib-resistant cells
12:30 - 12:30 | Author(s): Y. Chen
- Abstract
Loading... -
+
34P - Discovery of 1,3,5-triazine-monastrol based novel EGFR-tyrosine kinase inhibitor against human lung carcinoma
12:30 - 12:30 | Author(s): U.P. Singh
- Abstract
Loading... -
+
35P - CDK7 inhibition as a promising therapeutic strategy in lung squamous cell carcinoma with SOX2 amplification
12:30 - 12:30 | Author(s): J.C. Lee
- Abstract
Loading... -
+
36P - Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with nivolumab
12:30 - 12:30 | Author(s): F. Passiglia
- Abstract
Loading... -
+
37P - Can we perform subtyping of non-small cell lung cancer patients by use of lung tissue metabolic fingerprinting?
12:30 - 12:30 | Author(s): M. Ciborowski
- Abstract
Loading... -
+
38P - Flow cytometry immunophenotyping of pleural fluid cytology in patients with diffuse large B-cell lymphoma (DLBCL) and malignant pleural effusion
12:30 - 12:30 | Author(s): F. Lumachi
- Abstract
Loading... -
+
39P - Efficacy of Tumor Treating Fields (TTFields) and anti-PD-1 in non-small cell lung cancer (NSCLC) preclinical models
12:30 - 12:30 | Author(s): U. Weinberg
- Abstract
Loading... -
+
40P - Antitumoral effect and reduced systemic toxicity in mice after intra-tumoral injection of an in vivo solidifying calcium sulfate formulation with docetaxel
12:30 - 12:30 | Author(s): M. Sandelin
- Abstract
Loading... -
+
41P - Development of novel 1,2,4-triazole-thiol derivatives as dual PI3K/mTOR inhibitor against the non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Author(s): A. Verma
- Abstract
Loading... -
+
42P - Dual inhibitory effects of novel naringenin analogue in tobacco-carcinogen induced lung cancer via inhibition of PI3K/Akt/mTOR pathway
12:30 - 12:30 | Author(s): V. Kumar
- Abstract
Loading... -
+
43P - A phase I-II clinical trial to evaluate the safety, pharmacokinetics and efficacy of high dose intravenous ascorbic acid synergy with mEHT in Chinese patients with stage III-IV non-small cell lung cancer
12:30 - 12:30 | Author(s): J. Ou
- Abstract
Loading... -
+
Imaging and staging
12:30 - 12:30
- Abstract
No abstract available for this presentation
-
+
47P - Multi detector CT evaluation of suspicious malignant lung masses with its combined wash-in & wash-out features and their histopathological correlation
12:30 - 12:30 | Author(s): S. Khanduri
- Abstract
Loading... -
+
48P - Evaluation of neoplasms incidentally detected by preoperative FDG-PET/CT for primary lung cancer
12:30 - 12:30 | Author(s): Y. Noda
- Abstract
Loading... -
+
49P - Computed tomographic features of pulmonary sarcomatoid carcinoma
12:30 - 12:30 | Author(s): M. Attia
- Abstract
Loading... -
+
50P - Usefulness of F-18 FDG PET/CT to identify metastatic mediastinal lymph node in NSCLC patients with bilateral benign mediastinal lymph node hyperplasia
12:30 - 12:30 | Author(s): Y.S. Kim
- Abstract
Loading... -
+
SCLC
12:30 - 12:30
- Abstract
No abstract available for this presentation
-
+
52P - Combined chemotherapy with etoposide, irinotecan plus cisplatin compared with topotecan monotherapy as the second-line treatment in sensitive relapsed small cell lung cancer: A retrospective analysis
12:30 - 12:30 | Author(s): H. Wang
- Abstract
Loading... -
+
53P - Systematic literature reviews of second and third-line treatments used for small-cell lung cancer (SCLC)
12:30 - 12:30 | Author(s): R. Goulding
- Abstract
Loading... -
+
54P - Up front chemotherapy dosing and relative dose intensity in extensive stage small cell lung cancer
12:30 - 12:30 | Author(s): A.W. Mølby
- Abstract
Loading... -
+
55P - Clinical significance of EBUS-TBNA in patients with small cell lung cancer
12:30 - 12:30 | Author(s): Y.M. Lee
- Abstract
Loading... -
+
56P - Pro-GRP in small cell lung cancer
12:30 - 12:30 | Author(s): S. Cavalieri
- Abstract
Loading... -
+
57P - small cell lung cancer: Retrospective review of an institution
12:30 - 12:30 | Author(s): A. Silva
- Abstract
Loading... -
+
58TiP - IMpower133: Phase I/III trial of first-line atezolizumab with carboplatin and etoposide in ES-SCLC
12:30 - 12:30 | Author(s): M. Reck
- Abstract
Loading... -
+
Early stage NSCLC
12:30 - 12:30
- Abstract
No abstract available for this presentation
-
+
62P - Risk factors associated with early vs late recurrence in stage I lung adenocarcinoma
12:30 - 12:30 | Author(s): J. Qian
- Abstract
Loading... -
+
63P - Diabetes predisposes patients to atrial fibrillation after robotic-assisted video-thoracoscopic pulmonary lobectomy
12:30 - 12:30 | Author(s): S. Reynolds
- Abstract
Loading... -
+
64P - Smoking history as a risk factor for atrial fibrillation following robotic-assisted video-thoracoscopic pulmonary lobectomy
12:30 - 12:30 | Author(s): J. Glover
- Abstract
Loading... -
+
65P - Lymph node metastases in clinically node negative peripheral non-small cell lung cancer
12:30 - 12:30 | Author(s): T. Mehmood
- Abstract
Loading... -
+
66P - Effect of age on risk for atrial fibrillation following robotic-assisted video-thoracoscopic pulmonary lobectomy
12:30 - 12:30 | Author(s): J. Glover
- Abstract
Loading... -
+
67P - CT-guided fine-needle aspiration biopsy of pulmonary lesions under 15 mm of diameter: Results on 68 consecutive patients
12:30 - 12:30 | Author(s): D. Tosi
- Abstract
Loading... -
+
68P - Circulating tumor cells spillage after lung nodule biopsy
12:30 - 12:30 | Author(s): M. Sarfaty
- Abstract
Loading... -
+
69P - CT-Guided radiofrequency ablation of early stage NSCLC
12:30 - 12:30 | Author(s): X. Zhang
- Abstract
Loading... -
+
70P - A retrospective analysis to explore the value of gemcitabine combined with cisplatin as adjuvant chemotherapy of NSCLC
12:30 - 12:30 | Author(s): D. Ma
- Abstract
Loading... -
+
71TiP - A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (EORTC/ETOP 1416-PEARLS)
12:30 - 12:30 | Author(s): L. Paz-Ares
- Abstract
Loading... -
+
Locally advanced NSCLC
12:30 - 12:30
- Abstract
No abstract available for this presentation
-
+
75P - Predictive value of CT texture analysis in lung cancer patients undergoing nivolumab
12:30 - 12:30 | Author(s): V. Nardone
- Abstract
Loading... -
+
76P - Interpretation and prognostic value of PET-CT after induction chemotherapy with or without radiation in IIIA-N2 non-small cell lung cancer patients who receive curative surgery
12:30 - 12:30 | Author(s): J.H. Lee
- Abstract
Loading... -
+
77P - Bronchoscopic photodynamic therapy for treatment of microscopic residual disease post resection in non-small cell lung cancer
12:30 - 12:30 | Author(s): A. Biswas
- Abstract
Loading... -
+
78P - Comparison of chemoradiotherapy treatment strategies in stage III non-small cell lung cancer among elderly patients from multiple data sources
12:30 - 12:30 | Author(s): H. Pang
- Abstract
Loading... -
+
79P - Long term survival of stage IIIB non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiation
12:30 - 12:30 | Author(s): T. Mehmood
- Abstract
Loading... -
+
80TiP - A feasibility trial evaluating the addition of nivolumab to standard first-line chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: The ETOP 6-14 NICOLAS trial
12:30 - 12:30 | Author(s): S. Peters
- Abstract
Loading... -
+
Advanced NSCLC
12:30 - 12:30
- Abstract
No abstract available for this presentation
-
+
97P - Brigatinib in crizotinib-refractory ALK+ NSCLC: Updates from the pivotal randomized phase 2 Trial (ALTA)
12:30 - 12:30 | Author(s): M.J. Hochmair
- Abstract
Loading... -
+
98P - Retrospective indirect comparison of alectinib phase II data vs ceritinib real-world data in ALK+ NSCLC after progression on crizotinib
12:30 - 12:30 | Author(s): J. Davies
- Abstract
Loading... -
+
99P - Efficacy of gefitinib in advanced squamous cell lung cancer harboring epidermal growth factor receptor mutations: A pooled analysis of individual patient data
12:30 - 12:30 | Author(s): D. Tao
- Abstract
Loading... -
+
100P - Afatinib vs gefitinib for treatment-naïve patients with EGFRm+ NSCLC (LUX-Lung 7): Analysis of time to treatment failure and impact of afatinib dose adjustment
12:30 - 12:30 | Author(s): J.C. Yang
- Abstract
Loading... -
+
101P - Association between time to progression and subsequent survival in previously treated BRAF V600E-mutant metastatic non-small cell lung cancer
12:30 - 12:30 | Author(s): M. Sasane
- Abstract
Loading... -
+
102P - LUX-Lung 8 phase III trial: Analysis of long-term response to second-line afatinib in patients with advanced squamous cell carcinoma (SCC) of the lung
12:30 - 12:30 | Author(s): J.C. Yang
- Abstract
Loading... -
+
103P - Re-biopsy for advanced non-small cell lung cancer after EGFR tyrosine kinase inhibitor therapy: CT characteristics of patients with T790M mutation and the use of various re-biopsy procedures
12:30 - 12:30 | Author(s): H.J. Koo
- Abstract
Loading... -
+
104P - Efficacy of ceritinib in a "real-world" population of crizotinib-refractory ALK-positive NSCLCs: Results of the Italian compassionate use program
12:30 - 12:30 | Author(s): G. Metro
- Abstract
Loading... -
+
105P - Prognostic factors in crizotinib (CRZ)-resistant anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) patients (Pts)
12:30 - 12:30 | Author(s): K.L. Reckamp
- Abstract
Loading... -
+
106P - Brain metastases (BM) development in molecular selected non-small cell lung cancer (NSCLC) patients included in clinical trials
12:30 - 12:30 | Author(s): S. Cedres
- Abstract
Loading... -
+
107P - The real world experience of first generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in patients with advanced lung cancer: Explorative analysis of big data from national health insurance service of Korea
12:30 - 12:30 | Author(s): B.S. Kwon
- Abstract
Loading... -
+
108P - NSCLC patients harbouring a rare or complex EGFR mutation are more often smokers and might not benefit from first line TKI therapy
12:30 - 12:30 | Author(s): D. Kauffmann-Guerrero
- Abstract
Loading... -
+
109P - Sequential administration of EGFR-TKI and pemetrexed achieved a long period of response in advanced NSCLC patients with EGFR-mutant tumors
12:30 - 12:30 | Author(s): Y. Chen
- Abstract
Loading... -
+
110P - Afatinib for patients with advanced NSCLC pretreated with chemotherapy and an EGFR tyrosine kinase inhibitor: Retrospective analysis of the Swiss Afatinib Named Patient Program
12:30 - 12:30 | Author(s): M. Ehmann
- Abstract
Loading... -
+
111P - Pharmacist led proactive follow-up algorithm for advanced EGFR positive NSCLC patients on afatinib
12:30 - 12:30 | Author(s): P.K. Cheema
- Abstract
Loading... -
+
112P_PR - Immune response and adverse events to influenza vaccine in cancer patients undergoing PD-1 blockade
12:30 - 12:30 | Author(s): S.I. Rothschild
- Abstract
Loading... -
+
113P - Clinical outcomes and quality of life (QoL) in adults with advanced refractory non-small cell lung cancer (NSCLC) patients receiving nivolumab (Nivo) as 2+ line treatment: Interim analysis of expanded access program
12:30 - 12:30 | Author(s): K.K. Laktionov
- Abstract
Loading... -
+
114P - Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea
12:30 - 12:30 | Author(s): E.K. Cho
- Abstract
Loading... -
+
115P - Immune related adverse events (irAE) and disease response with nivolumab in pre-treated advanced non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Author(s): E. Connolly
- Abstract
Loading... -
+
116P - A randomized study to evaluate safety of DCVAC/LUCA added to chemotherapy with carboplatin and pemetrexed vs. chemotherapy alone in patients with stage IV non-small cell lung cancer
12:30 - 12:30 | Author(s): H. Zhong
- Abstract
Loading... -
+
117P - Symptomatic pneumonitis in the irradiated lung after nivolumab: Three case studies
12:30 - 12:30 | Author(s): O. Roengvoraphoj
- Abstract
Loading... -
+
118P - Early onset of endocrine alterations during PD-1 blockade in advanced NSCLC patients
12:30 - 12:30 | Author(s): C.E. Onesti
- Abstract
Loading... -
+
119P - A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts
12:30 - 12:30 | Author(s): S. Thomas
- Abstract
Loading... -
+
120P - Subgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC)
12:30 - 12:30 | Author(s): M. Reck
- Abstract
Loading... -
+
121P - Safety and efficacy of bevacizumab in "fragile" patients with advanced non-small cell lung cancer
12:30 - 12:30 | Author(s): C. Maragkos
- Abstract
Loading... -
+
122P - Response to Metabolically Supported Chemotherapy (MSCT) with weekly carboplatin/paclitaxel in advanced stage/metastatic (Stage IV) non-small cell lung cancer: A survival, efficacy and tolerability analysis
12:30 - 12:30 | Author(s): M.S. Iyikesici
- Abstract
Loading... -
+
123P - A retrospective study in Chinese patients: Is there a role of nanoparticle albumin bound paclitaxel in advanced NSCLC?
12:30 - 12:30 | Author(s): Y. Zhu
- Abstract
Loading... -
+
124P - Driverless lung carcinoma: Impact of expanded RNA and protein-based testing on detection of actionable biomarkers
12:30 - 12:30 | Author(s): Z. Gatalica
- Abstract
Loading... -
+
125P - Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma Patients (CRISP): A prospective German registry in stage IV NSCLC, AIO-TRK-0315
12:30 - 12:30 | Author(s): F. Griesinger
- Abstract
Loading... -
+
126P - The clinical impact of multiplex ctDNA gene analysis in lung cancer
12:30 - 12:30 | Author(s): S. Geva
- Abstract
Loading... -
+
127P - Prognostic significance of advanced lung cancer inflammation index (ALI) In untreated and treated stage IV non-small cell lung cancer (NSCLC): An Australian cancer centre experience
12:30 - 12:30 | Author(s): H. Mandaliya
- Abstract
Loading... -
+
128P - Serum DKK-1 as a clinical and prognostic factor in non-small cell lung cancer patients with bone metastases
12:30 - 12:30 | Author(s): R. Qiao
- Abstract
Loading... -
+
129P - Procathepsin D as a novel diagnostic marker for malignant pleural effusion of lung cancer
12:30 - 12:30 | Author(s): C.Y. Lee
- Abstract
Loading... -
+
130P - EGFR mutations in lung adenocarcinoma and brain metastases: A Croatian single institution experience
12:30 - 12:30 | Author(s): K.B. Sreter
- Abstract
Loading... -
+
131P - T790M co-exists with other secondary resistance mechanisms in EGFR mutation positive NSCLC and are associated with inferior outcomes
12:30 - 12:30 | Author(s): R. Teng
- Abstract
Loading... -
+
132P - Real world treatment patterns and outcomes for mNSCLC patients receiving second and third-line therapy in Germany
12:30 - 12:30 | Author(s): N. Yu
- Abstract
Loading... -
+
133P - The influence of body composition on TTFields intensity in the lungs
12:30 - 12:30 | Author(s): U. Weinberg
- Abstract
Loading... -
+
134P - Applicable CT-guided percutaneous radiofrequency ablation (RFA) in the treatment of unresectable Lung Ground Glass Opacity (GGO)
12:30 - 12:30 | Author(s): Y.T. Wei
- Abstract
Loading... -
+
135P - Coxsackievirus type B3 is a potent oncolytic virus against KRAS-mutant non-small cell lung cancer
12:30 - 12:30 | Author(s): H. Deng
- Abstract
Loading... -
+
136P - Long-term safety and efficacy of darbepoetin alfa in subjects with stage IV NSCLC receiving multi-cycle chemotherapy
12:30 - 12:30 | Author(s): P. Gascón
- Abstract
Loading... -
+
137P - Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in France after a first-line platinum based therapy
12:30 - 12:30 | Author(s): M. Pignata
- Abstract
Loading... -
+
138TiP - An open-label phase 3b/4 safety trial of flat-dose nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Author(s): L. Paz-Ares
- Abstract
Loading... -
+
139TiP - A non-interventional biomarker study in patients (pts) with non-small cell lung cancer (NSCLC) of adenocarcinoma histology who are treated with nintedanib according to the approved label (LUME-BioNIS)
12:30 - 12:30 | Author(s): M. Reck
- Abstract
Loading... -
+
140TiP - CheckMate 384: A phase 3b/4 dose-frequency optimization trial of nivolumab in advanced or metastatic non-small cell lung cancer
12:30 - 12:30 | Author(s): N. Reinmuth
- Abstract
Loading... -
+
141TiP - ASTRIS: A multicenter, real world treatment study of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Author(s): P.K. Cheema
- Abstract
Loading... -
+
142TiP - A prospective multi-center study to investigate the EGFR-TKI resistance profile, treatment algorithm and clinical outcome in Chinese patients with advanced EGFRm+ NSCLC who have received prior first generation EGFR TKI (PRECENT study, CCTC-1601, NCT02988141)
12:30 - 12:30 | Author(s): W. Liang
- Abstract
Loading... -
+
143TiP - IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC
12:30 - 12:30 | Author(s): J. Jassem
- Abstract
Loading... -
+
144TiP - CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Author(s): L. Paz-Ares
- Abstract
Loading... -
+
145TiP - TTFields combined with PD-1 inhibitors or docetaxel for 2nd line treatment of non-small cell lung cancer (NSCLC): Phase 3 LUNAR study
12:30 - 12:30 | Author(s): U. Weinberg
- Abstract
Loading... -
+
146TiP - EXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Author(s): L. Horn
- Abstract
Loading... -
+
Metastases to and from the lung
12:30 - 12:30
- Abstract
No abstract available for this presentation
-
+
148P - Metastatic site location may influence the diagnostic accuracy of plasma EGFR-mutation testing in NSCLC: A pooled analysis
12:30 - 12:30 | Author(s): F. Passiglia
- Abstract
Loading... -
+
149P - PD-L1 expression patterns in the metastatic tumors to the lung: A comparative study with the primary non-small cell lung cancer
12:30 - 12:30 | Author(s): Z. Gatalica
- Abstract
Loading... -
+
150P - Immunohistochemical characteristics of brain metastases and corresponding primary lung cancer
12:30 - 12:30 | Author(s): D. Marinova
- Abstract
Loading... -
+
151P - Predictors of survival in patients with bone metastasis of lung cancer
12:30 - 12:30 | Author(s): S. Jagadeesan
- Abstract
Loading... -
+
152P - Relationship between overall survival and preoperative parameters in patients with colorectal cancer and synchronous liver and lung metastases
12:30 - 12:30 | Author(s): F. Lumachi
- Abstract
Loading... -
+
153P - Predictive markers of survival in patients with pulmonary metastases and malignant pleural effusion
12:30 - 12:30 | Author(s): F. Lumachi
- Abstract
Loading... -
+
154P - Analysis of factors affecting survival in patients with simultaneous liver and pulmonary metastases from colorectal cancer
12:30 - 12:30 | Author(s): F. Lumachi
- Abstract
Loading... -
+
155P - Combination of hepatic surgery and minimally invasive thoracic surgery using a subxyphoid approach through an abdominal incision
12:30 - 12:30 | Author(s): M. Lim
- Abstract
Loading... -
+
156P - Clinical outcome of cyberknife radiosurgery in brain metastases of non-small cell lung cancer: A single institutional experience
12:30 - 12:30 | Author(s): S. Lee
- Abstract
Loading... -
+
157P - Mediastinal masses: A study of our cases by transthoracic needle biopsy (TTNB) versus open surgery as a diagnostic procedure
12:30 - 12:30 | Author(s): F. Gradica
- Abstract
Loading... -
+
158TiP - Open label, multi-center, prospective study to investigate the efficacy and safety of osimertinib in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI (APOLLO Study, NCT02972333)
12:30 - 12:30 | Author(s): L. Wang
- Abstract
Loading... -
+
159TiP - TTFields and radiosurgery for 1-10 brain metastases from NSCLC: The Phase 3 METIS study
12:30 - 12:30 | Author(s): M.P. Mehta
- Abstract
Loading... -
+
160P - BAP1 in advanced sporadic malignant pleural mesothelioma
12:30 - 12:30 | Author(s): A. El Bastawisy
- Abstract
Loading... -
+
161P - DKK1 stabilization as a new malignant pleural mesothelioma therapeutic avenue
12:30 - 12:30 | Author(s): A. Guazzelli
- Abstract
Loading... -
+
162P - Targeting the RON/MET/TAM signalling network in mesothelioma
12:30 - 12:30 | Author(s): A. Baird
- Abstract
Loading... -
+
164P - Heart radiation dose as a risk factor for dyspnea worsening after multimodality treatment for non-small cell lung cancer and pleural mesothelioma: An exploratory analysis
12:30 - 12:30 | Author(s): A. Botticella
- Abstract
Loading... -
+
165P - Malignant pleural mesothelioma: A systematic review of first-line chemotherapy and analysis of Hong Kong cohort
12:30 - 12:30 | Author(s): H. Pang
- Abstract
Loading... -
+
166P - Thymoma and thymic carcinoma: A real-life retrospective analysis
12:30 - 12:30 | Author(s): I. Attili
- Abstract
Loading... -
+
167P - Role of surgery in the treatment of thymic carcinoma based on a 5-year experience
12:30 - 12:30 | Author(s): F.F. Caushi
- Abstract
Loading... -
+
168P - Clinical and prognostic characteristics of primary pulmonary non-Hodgkin’s lymphoma: A retrospective analysis of 38 cases in a Chinese population
12:30 - 12:30 | Author(s): R. Qiao
- Abstract
Loading... -
+
169P - Pulmonary carcinoid tumors: Experience from an oncology center
12:30 - 12:30 | Author(s): L. Bei
- Abstract
Loading... -
+
170TiP - LUME-Meso: Randomised phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM)
12:30 - 12:30 | Author(s): S. Popat
- Abstract
Loading...
-
+
Industry Satellite Symposium 6
- Type: Industry Satellite Symposium
- Presentations: 1
- Coordinates: 5/07/2017, 13:00 - 14:00, Room A
-
+
Treatment of advanced NSCLC: State of the art today & promises for the future
13:00 - 14:00 | Author(s): S. Peters
- Abstract
No abstract available for this presentation
-
+
Industry Satellite Symposium 7
- Type: Industry Satellite Symposium
- Presentations: 1
- Coordinates: 5/07/2017, 13:00 - 14:00, Room C
-
+
Sharing our knowledge in NSCLC: Case interchange of real-world experience
13:00 - 14:00 | Author(s): R..A. Stahel
- Abstract
No abstract available for this presentation